Scarica l'app Stockscreener
20.68
0.39%
0.08
Dopo l'orario di chiusura:
20.78
0.10
+0.48%
Definium Therapeutics Inc Borsa (DFTX) Ultime notizie
Price performance - Yahoo Finance Singapore
Do Definium Therapeutics’ (DFTX) New Hires Hint At A Deeper Bet On Anxiety Treatments? - Sahm
Can Definium Therapeutics (DFTX) Turn GAD Prevalence And DT120 Breakthrough Status Into Durable Advantage? - Yahoo Finance
Total non-current liabilities of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
Definium Therapeutics stock hits 52-week high at 19.78 USD By Investing.com - Investing.com Canada
Definium Therapeutics (NASDAQ:DFTX) Sets New 52-Week HighHere's Why - marketbeat.com
Definium Therapeutics stock hits 52-week high at 19.78 USD - Investing.com
New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States - BioSpace
Definium Therapeutics (DFTX) Study Highlights Rising GAD Rates i - GuruFocus
Anxiety disorder prevalence rises to 6.6% in U.S., study finds By Investing.com - Investing.com Australia
Anxiety disorder prevalence rises to 6.6% in U.S., study finds - Investing.com
Definium Therapeutics Inc (DFTX) Stock Price Quote Today & Current Price Chart - Capital.com
Definium Therapeutics Announces New Employee Inducement Grants - Yahoo Finance
A Look At Definium Therapeutics (DFTX) Valuation As Investor Day Highlights Late Stage DT120 ODT Pipeline - Sahm
Definium Therapeutics, Inc. (NASDAQ:DFTX) Short Interest Update - Defense World
symbol__ Stock Quote Price and Forecast - CNN
Definium Therapeutics Insider Sold Shares Worth $451,241, According to a Recent SEC Filing - MarketScreener
Definium Therapeutics chief legal officer sells $197k in shares By Investing.com - Investing.com South Africa
Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026 - BioSpace
Definium Therapeutics CMO Karlin sells $148k in shares By Investing.com - Investing.com Australia
Definium Therapeutics CEO Barrow sells $451k in shares By Investing.com - Investing.com India
Definium Therapeutics CEO Barrow sells $451k in shares - Investing.com
Definium Therapeutics CMO Karlin sells $148k in shares - Investing.com
Definium Therapeutics chief legal officer sells $197k in shares - Investing.com
Definium (NASDAQ: DFTX) CMO sells shares to cover RSU tax - Stock Titan
Tax-cover sale by Definium (DFTX) legal chief totals 10,702 shares - Stock Titan
Definium Therapeutics (DFTX) CEO share sale covers RSU tax withholding - stocktitan.net
Definium Therapeutics brings Investor and Analyst Day event to New York - Traders Union
Robert Barrow files to sell 24,431 DFTX shares (DFTX) - Stock Titan
Affiliate sale notice for DFTX (NASDAQ: DFTX) — 8,018 shares reported - Stock Titan
Mark Sullivan to sell 10,702 shares (DFTX) under registered plan - Stock Titan
A Look At Definium Therapeutics (DFTX) Valuation After Its Recent Name Change And Share Price Momentum - Yahoo Finance
Definium Therapeutics Inc (DFTX) Says Cash Enough to Fund Operations into 2028 - Insider Monkey
9 Best Psychedelic Stocks to Buy in 2026 - Insider Monkey
Biotech Firm Developing LSD-Based Psychiatric Treatments Moves to Dismiss Trade Secrets Lawsuit, Calls Claims by Former Clinical Trial Vendor Legally Deficient - USA Herald
Definium Therapeutics stock hits 52-week high at 19.66 USD By Investing.com - Investing.com Australia
Definium Therapeutics (NASDAQ:DFTX) Sets New 12-Month HighHere's Why - MarketBeat
Definium Therapeutics stock hits 52-week high at 19.66 USD - Investing.com
Definium Therapeutics Teases 3 Key DT-120 Data Readouts This Year, Highlights De-Risked Phase 3 Design - MarketBeat
Superstring Capital's Definium Therapeutics Investment: Q4 2025 PositionNews and Statistics - IndexBox
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names - AOL.com
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):